Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ruby F Meredith

Showing results (21-30 of 52) with videos related to

Pageof 6
Sort By:
Cancer Biotherapy & Radiopharmaceuticals|June 20, 2014
Pazopanib combined with radiation: in vivo model of interactionRuby F Meredith, Kevin P Raisch, James A Bonner, et al.
Cancer Biotherapy & Radiopharmaceuticals|November 25, 2003
A novel monoclonal antibody design for radioimmunotherapyAndres Forero, Ruby F Meredith, M B Khazaeli, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 6, 2005
Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignanciesSui Shen, Andres Forero, Albert F LoBuglio, et al.
Lung Cancer (Amsterdam, Netherlands)|July 26, 2002
Concurrent chemoradiation therapy with cisplatin and paclitaxel for locally advanced non-small cell lung cancer: long-term follow-up of a phase I trialFrancisco Robert, Sharon A Spencer, Hoyt A Childs, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 17, 2009
Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphomaSui Shen, Andres Forero, Ruby F Meredith, et al.
Cancer|March 6, 2002
Rationales, evidence, and design considerations for fractionated radioimmunotherapyGerald L DeNardo, Jeffery Schlom, Donald J Buchsbaum, et al.
Cancer Biotherapy & Radiopharmaceuticals|March 28, 2013
Phase I study of a modified regimen of ⁹⁰Yttrium-ibritumomab tiuxetan for relapsed or refractory follicular or transformed CD20+ non-Hodgkin lymphomaChristos Vaklavas, Ruby F Meredith, Sui Shen, et al.
Cancer Biotherapy & Radiopharmaceuticals|October 27, 2005
Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: effect of chelating agents and paclitaxel co-administrationAndres Forero, Ruby F Meredith, M B Khazaeli, et al.
Cancer Biotherapy & Radiopharmaceuticals|November 16, 2013
Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patientsRuby F Meredith, Julien Torgue, Michael T Azure, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 9, 2004
Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparisonBarry W Wessels, Wesley E Bolch, Lionel G Bouchet, et al.
Pageof 6

Showing results (21-30 of 52) with videos related to

Sort By:
Pageof 6
Cancer Biotherapy & Radiopharmaceuticals|June 20, 2014
Pazopanib combined with radiation: in vivo model of interactionRuby F Meredith, Kevin P Raisch, James A Bonner, et al.
Cancer Biotherapy & Radiopharmaceuticals|November 25, 2003
A novel monoclonal antibody design for radioimmunotherapyAndres Forero, Ruby F Meredith, M B Khazaeli, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 6, 2005
Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignanciesSui Shen, Andres Forero, Albert F LoBuglio, et al.
Lung Cancer (Amsterdam, Netherlands)|July 26, 2002
Concurrent chemoradiation therapy with cisplatin and paclitaxel for locally advanced non-small cell lung cancer: long-term follow-up of a phase I trialFrancisco Robert, Sharon A Spencer, Hoyt A Childs, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 17, 2009
Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphomaSui Shen, Andres Forero, Ruby F Meredith, et al.
Cancer|March 6, 2002
Rationales, evidence, and design considerations for fractionated radioimmunotherapyGerald L DeNardo, Jeffery Schlom, Donald J Buchsbaum, et al.
Cancer Biotherapy & Radiopharmaceuticals|March 28, 2013
Phase I study of a modified regimen of ⁹⁰Yttrium-ibritumomab tiuxetan for relapsed or refractory follicular or transformed CD20+ non-Hodgkin lymphomaChristos Vaklavas, Ruby F Meredith, Sui Shen, et al.
Cancer Biotherapy & Radiopharmaceuticals|October 27, 2005
Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: effect of chelating agents and paclitaxel co-administrationAndres Forero, Ruby F Meredith, M B Khazaeli, et al.
Cancer Biotherapy & Radiopharmaceuticals|November 16, 2013
Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patientsRuby F Meredith, Julien Torgue, Michael T Azure, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 9, 2004
Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparisonBarry W Wessels, Wesley E Bolch, Lionel G Bouchet, et al.
Pageof 6